Therapeutic bacteriophage compositions
The present invention relates to a bacteriophage composition comprising one or more (suitably two or more, or three) bacteriophages selected from Sa87, J-Sa36, or Sa83, or mutants thereof. Also encompassed are the use of said bacteriophage compositions for medical or non-medical applications, as well as kits, bandages, and wound dressings comprising said bacteriophage compositions.
1 . A therapeutic bacteriophage composition formulated for treating a bacterial infection in a human subject in need thereof, comprising one or more bacteriophages selected from a bacteriophage having at least 90% sequence identity across its entire genome when compared to Sa87 (SEQ ID NO:2), a bacteriophage having at least 90% sequence identity across its entire genome when compared to J-Sa36 (SEQ ID NO:3), a bacteriophage having at least 90% sequence identity across its entire genome when compared to Sa83 (SEQ ID NO:4); and wherein the composition comprises a single dosage of 1×10 7 to 1×10 11 PFU of each phage per mL of composition.
2 . A bacteriophage composition according to claim 1 comprising at least two bacteriophages selected from a bacteriophage having at least 90% sequence identity across its entire genome when compared to Sa87 (SEQ ID NO:2), a bacteriophage having at least 90% sequence identity across its entire genome when compared to J-Sa36 (SEQ ID NO:3), and a bacteriophage having at least 90% sequence identity across its entire genome when compared to Sa83 (SEQ ID NO:4).
3 . A bacteriophage composition according to claim 1 , comprising bacteriophages having at least 97% sequence identity to each of Sa87 (SEQ ID NO:2), J-Sa36 (SEQ ID NO:3), and Sa83 (SEQ ID NO:4).
4 . A bacteriophage composition according to claim 1 consisting essentially of bacteriophage having at least 98% sequence identity to each of Sa87 (SEQ ID NO:2), J-Sa36 (SEQ ID NO:3), and Sa83 (SEQ ID NO:4).
5 . A bacteriophage composition according to claim 1 , wherein the one or more bacteriophages has at least 95% sequence identity across its entire genome when compared to Sa87 (SEQ ID NO:2), at least 95% sequence identity across its entire genome when compared to J-Sa36 (SEQ ID NO:3), or at least 95% sequence identity across its entire genome when compared to Sa83 (SEQ ID NO:4).
6 . A bacteriophage composition according to claim 1 , further comprising a pharmaceutically acceptable carrier, diluent, excipient or combinations thereof.
7 . A bacteriophage composition according to claim 1 for use as a medicament.
8 . A bacteriophage composition according to claim 1 for use in treating a bacterial infection.
9 . A method of treating a bacterial infection comprising administering the bacteriophage composition according to claim 1 to a subject.
10 . A method according to claim 9 , wherein the bacterial infection is a Staphylococcus aureus bacterial infection.
11 . The method of claim 10 , wherein the bacterial infection is a pulmonary bacterial infection.
12 . A kit comprising:
a. a bacteriophage composition comprising one or more bacteriophages selected from a bacteriophage having at least 90% sequence identity across its entire genome when compared to Sa87 (SEQ ID NO:2), a bacteriophage having at least 90% sequence identity across its entire genome when compared to J-Sa36 (SEQ ID NO:3), and a bacteriophage having at least 90% sequence identity across its entire genome when compared to Sa83 (SEQ ID NO:4), for use in a method of treating a pulmonary bacterial infection; and
b. instructions for use of the composition.
13 . A kit according to claim 12 , further comprising an antibiotic and instructions for use of the antibiotic in combination with the bacteriophage composition.
14 . A kit according to claim 12 , wherein said instructions are for use of the composition in treating a pulmonary Staphylococcus aureus infection.
15 . A method of killing bacteria on a surface, said method comprising applying a bacteriophage composition according to claim 1 to the surface.
16 . A method according to claim 15 , wherein the surface is the skin of a mammal, equipment, bedding, furniture, walls, floors, or combinations thereof.
17 . The method of claim 16 , wherein the equipment is medical equipment.
18 . The composition of claim 1 , further comprising an antibiotic.
19 . The composition of claim 1 , wherein the composition comprises about 1×10 11 PFU/mL per phage.
20 . The kit of claim 12 , wherein the composition comprises about 1×10 11 PFU/mL per phage.
21 . The composition of claim 1 , wherein the bacterial infection comprises a Staphylococcus aureus infection.
22 . A method of treating a bacterial infection comprising administering the bacteriophage composition according to claim 2 to a subject.
23 . A method of treating a bacterial infection comprising administering the bacteriophage composition according to claim 3 to a subject.
24 . A method of treating bacterial infection comprising administering the bacteriophage composition according to claim 4 to a subject.
25 . A method of treating a bacterial infection comprising administering the bacteriophage composition according to claim 5 to a subject.
26 . The composition of claim 1 , wherein the one or more bacteriophages comprises a bacteriophage having at least 90% sequence identity across its entire genome when compared to Sa87 (SEQ ID NO:2).
27 . The composition of claim 1 , wherein the one or more bacteriophages comprises a bacteriophage having at least 90% sequence identity across its entire genome when compared to J-Sa36 (SEQ ID NO:3).
28 . The composition of claim 1 , wherein the one or more bacteriophages comprises a bacteriophage having at least 90% sequence identity across its entire genome when compared to Sa83 (SEQ ID NO:4).
29 . The composition of claim 1 , wherein the one or more bacteriophages comprises a bacteriophage having at least 95% sequence identity across its entire genome when compared to Sa87 (SEQ ID NO:2).
30 . The composition of claim 1 , wherein the one or more bacteriophages comprises a bacteriophage having at least 95% sequence identity across its entire genome when compared to J-Sa36 SEQ ID NO:3).
31 . The composition of claim 1 , wherein the one or more bacteriophages comprises a bacteriophage having at least 95% sequence identity across its entire genome when compared to Sa83 (SEQ ID NO:4).